The HPV 9-10 Trial: Early Initiation of HPV Vaccination

NARecruitingINTERVENTIONAL
Enrollment

3,100

Participants

Timeline

Start Date

December 23, 2019

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2027

Conditions
HPV
Interventions
BEHAVIORAL

(Intervention) Recommending HPV vaccine for patients 9-10 years of age

Practices are randomized to receive training on how to recommend HPV vaccine, including both standardized communication strategies and strategies for switching from 11-12 years to 9-10 years including: challenges with 11-12 strategy, long-term immunity, success of other practices and tips to help standardize to age 9-10. Trainings will be a combination of online and in-person or virtual. Annual trainings will be offered and providers will receive Maintenance of Certification credits (MOC) for participating. Providers will routinely recommend HPV starting at age 9 for all patients -- which is already approved for this vaccine but is not routinely recommended at age 9 years.

BEHAVIORAL

(Control) Recommending HPV vaccine for patients 11-12 years of age

Control practices will receive a training on standardized communication for HPV vaccine including: using strong recommendations, using presumptive recommendation, providing specific phrases to use with parents, answering common questions and, HPV vaccine as a cancer prevention. Annual trainings will be offered and providers will receive professional development credit (MOC).

Trial Locations (2)

80045

RECRUITING

University of Colorado, Aurora

90095

RECRUITING

University of California at Los Angeles, Los Angeles

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Colorado, Denver

OTHER

NCT04722822 - The HPV 9-10 Trial: Early Initiation of HPV Vaccination | Biotech Hunter | Biotech Hunter